116 related articles for article (PubMed ID: 36579759)
1. Active surveillance in younger patients with prostate cancer: clinical characteristics including longitudinal patient-reported outcomes.
Tohi Y; Kato T; Matsuda I; Honda T; Osaki Y; Naito H; Matsuoka Y; Okazoe H; Taoka R; Ueda N; Sugimoto M
Jpn J Clin Oncol; 2023 Mar; 53(4):335-342. PubMed ID: 36579759
[TBL] [Abstract][Full Text] [Related]
2. Health-related quality of life in Japanese low-risk prostate cancer patients choosing active surveillance: 3-year follow-up from PRIAS-JAPAN.
Hirama H; Sugimoto M; Miyatake N; Kato T; Venderbos LDF; Remmers S; Shiga K; Yokomizo A; Mitsuzuka K; Matsumoto R; Osawa T; Abe T; Sasaki H; Egawa S; Ninomiya I; Hashine K; Roobol MJ; Kakehi Y
World J Urol; 2021 Jul; 39(7):2491-2497. PubMed ID: 33079252
[TBL] [Abstract][Full Text] [Related]
3. Long-term Psychological and Quality-of-life Effects of Active Surveillance and Watchful Waiting After Diagnosis of Low-risk Localised Prostate Cancer.
Egger SJ; Calopedos RJ; O'Connell DL; Chambers SK; Woo HH; Smith DP
Eur Urol; 2018 Jun; 73(6):859-867. PubMed ID: 28851582
[TBL] [Abstract][Full Text] [Related]
4. Prospective Quality of Life in Men Choosing Active Surveillance Compared to Those Biopsied but not Diagnosed with Prostate Cancer.
Pham KN; Cullen J; Hurwitz LM; Wolff EM; Levie KE; Odem-Davis K; Banerji JS; Rosner IL; Brand TC; L'Esperance JO; Sterbis JR; Porter CR
J Urol; 2016 Aug; 196(2):392-8. PubMed ID: 26976206
[TBL] [Abstract][Full Text] [Related]
5. A prospective study of health-related quality-of-life outcomes for patients with low-risk prostate cancer managed by active surveillance or radiation therapy.
Banerji JS; Hurwitz LM; Cullen J; Wolff EM; Levie KE; Rosner IL; Brand TC; LʼEsperance JO; Sterbis JR; Porter CR
Urol Oncol; 2017 May; 35(5):234-242. PubMed ID: 28110975
[TBL] [Abstract][Full Text] [Related]
6. Association Between Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-Reported Outcomes After 3 Years.
Barocas DA; Alvarez J; Resnick MJ; Koyama T; Hoffman KE; Tyson MD; Conwill R; McCollum D; Cooperberg MR; Goodman M; Greenfield S; Hamilton AS; Hashibe M; Kaplan SH; Paddock LE; Stroup AM; Wu XC; Penson DF
JAMA; 2017 Mar; 317(11):1126-1140. PubMed ID: 28324093
[TBL] [Abstract][Full Text] [Related]
7. Health-related quality of life in active surveillance and radical prostatectomy for low-risk prostate cancer: a prospective observational study (HAROW - Hormonal therapy, Active Surveillance, Radiation, Operation, Watchful Waiting).
Ansmann L; Winter N; Ernstmann N; Heidenreich A; Weissbach L; Herden J
BJU Int; 2018 Sep; 122(3):401-410. PubMed ID: 29603553
[TBL] [Abstract][Full Text] [Related]
8. Active Surveillance of Prostate Cancer is a Viable Option for Men Younger than 60 Years.
Salari K; Kuppermann D; Preston MA; Dahl DM; Barrisford GW; Efstathiou JA; Blute ML; Vesprini D; Loblaw A; Zietman AL; Klotz L; Feldman AS
J Urol; 2019 Apr; 201(4):721-727. PubMed ID: 30664083
[TBL] [Abstract][Full Text] [Related]
9. Quality of Life Outcomes after Primary Treatment for Clinically Localised Prostate Cancer: A Systematic Review.
Lardas M; Liew M; van den Bergh RC; De Santis M; Bellmunt J; Van den Broeck T; Cornford P; Cumberbatch MG; Fossati N; Gross T; Henry AM; Bolla M; Briers E; Joniau S; Lam TB; Mason MD; Mottet N; van der Poel HG; Rouvière O; Schoots IG; Wiegel T; Willemse PM; Yuan CY; Bourke L
Eur Urol; 2017 Dec; 72(6):869-885. PubMed ID: 28757301
[TBL] [Abstract][Full Text] [Related]
10. Prospective quality-of-life outcomes for low-risk prostate cancer: Active surveillance versus radical prostatectomy.
Jeldres C; Cullen J; Hurwitz LM; Wolff EM; Levie KE; Odem-Davis K; Johnston RB; Pham KN; Rosner IL; Brand TC; L'Esperance JO; Sterbis JR; Etzioni R; Porter CR
Cancer; 2015 Jul; 121(14):2465-73. PubMed ID: 25845467
[TBL] [Abstract][Full Text] [Related]
11. Impact of health-related quality of life on repeat protocol biopsy compliance on active surveillance for favorable prostate cancer: results from a prospective cohort in the PRIAS-JAPAN study.
Tohi Y; Kato T; Yokomizo A; Mitsuzuka K; Tomida R; Inokuchi J; Matsumoto R; Saito T; Sasaki H; Inoue K; Kinoshita H; Fukuhara H; Maruyama S; Sakamoto S; Tanikawa T; Egawa S; Ichikura H; Abe T; Nakamura M; Kakehi Y; Sugimoto M
Urol Oncol; 2022 Feb; 40(2):56.e9-56.e15. PubMed ID: 34112576
[TBL] [Abstract][Full Text] [Related]
12. Health-related quality of life in men with prostate cancer undergoing active surveillance versus radical prostatectomy, external-beam radiotherapy, prostate brachytherapy and reference population: a cross-sectional study.
Sureda A; Fumadó L; Ferrer M; Garín O; Bonet X; Castells M; Mir MC; Abascal JM; Vigués F; Cecchini L; Suárez JF
Health Qual Life Outcomes; 2019 Jan; 17(1):11. PubMed ID: 30642340
[TBL] [Abstract][Full Text] [Related]
13. Prostate cancer active surveillance and health-related quality of life: results of the Finnish arm of the prospective trial.
Vasarainen H; Lokman U; Ruutu M; Taari K; Rannikko A
BJU Int; 2012 Jun; 109(11):1614-9. PubMed ID: 22044485
[TBL] [Abstract][Full Text] [Related]
14. Patient-reported health-related quality of life up to three years after the treatment with permanent brachytherapy: Outcome of the large-scale, prospective longitudinal study in Japanese-Prostate Cancer Outcome Study by Permanent I-125 Seed Implantation (J-POPS).
Koga H; Naito S; Ishiyama H; Yorozu A; Saito S; Kojima S; Higashide S; Kikuchi T; Nakamura K; Dokiya T; Fukushima M;
Brachytherapy; 2019; 18(6):806-813. PubMed ID: 31378511
[TBL] [Abstract][Full Text] [Related]
15. Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions.
Loeb S; Zhou Q; Siebert U; Rochau U; Jahn B; Mühlberger N; Carter HB; Lepor H; Braithwaite RS
Eur Urol; 2017 Dec; 72(6):899-907. PubMed ID: 28844371
[TBL] [Abstract][Full Text] [Related]
16. Long-term health-related quality of life after primary treatment for localized prostate cancer: results from the CaPSURE registry.
Punnen S; Cowan JE; Chan JM; Carroll PR; Cooperberg MR
Eur Urol; 2015 Oct; 68(4):600-8. PubMed ID: 25242555
[TBL] [Abstract][Full Text] [Related]
17. Patient-Reported Outcomes Through 5 Years for Active Surveillance, Surgery, Brachytherapy, or External Beam Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer.
Hoffman KE; Penson DF; Zhao Z; Huang LC; Conwill R; Laviana AA; Joyce DD; Luckenbaugh AN; Goodman M; Hamilton AS; Wu XC; Paddock LE; Stroup A; Cooperberg MR; Hashibe M; O'Neil BB; Kaplan SH; Greenfield S; Koyama T; Barocas DA
JAMA; 2020 Jan; 323(2):149-163. PubMed ID: 31935027
[TBL] [Abstract][Full Text] [Related]
18. Radical prostatectomy versus deferred treatment for localised prostate cancer.
Vernooij RW; Lancee M; Cleves A; Dahm P; Bangma CH; Aben KK
Cochrane Database Syst Rev; 2020 Jun; 6(6):CD006590. PubMed ID: 32495338
[TBL] [Abstract][Full Text] [Related]
19. Temporary Health Impact of Prostate MRI and Transrectal Prostate Biopsy in Active Surveillance Prostate Cancer Patients.
Shankar PR; Maturen KE; George AK; Borza T; Ellimoottil C; Montgomery JS; Wei JT; Denton BT; Davenport MS
J Am Coll Radiol; 2019 Oct; 16(10):1385-1392. PubMed ID: 30733160
[TBL] [Abstract][Full Text] [Related]
20. Patient-reported outcome measures after treatment for prostate cancer: Results from the Danish Prostate Cancer Registry (DAPROCAdata).
Nguyen-Nielsen M; Møller H; Tjønneland A; Borre M
Cancer Epidemiol; 2020 Feb; 64():101623. PubMed ID: 31760356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
